The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours.
5 Stocks To Watch For December 23, 2021
Some of the stocks that may grab investor focus today are:
Banner Corporation (NASDAQ: BANR) reported a buyback of 1.71 million shares, which is the equivalent of around 5% of its common stock. Banner shares gained 0.6% to $58.98 in the after-hours trading session.
Arcutis Biotherapeutics Q3 EPS $(1.14) Down From $(1.01) YoY
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(1.14) per share. This is a 12.87 percent decrease over losses of $(1.01) per share from the same period last year.
Arcutis Biotherapeutics Highlights New Patent Issued By US Patent & Trademark Office ‘covering its invention for improving delivery and extending half-life of both the cream and foam formulations of topical roflumilast’
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with
Arcutis Biotherapeutics to Present Data At European Academy of Dermatology and Venereology (EADV) Congress.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with
Arcutis Biotherapeutics Q2 EPS $(0.84) Up From $(0.94) YoY
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.84) per share. This is a 10.64 percent increase over losses of $(0.94) per share from the same period last year.
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Lowers Price Target to $50
Morgan Stanley analyst David Lebowitz maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and lowers the price target from $52 to $50.
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological